ES2394349A8 - Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar - Google Patents

Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar Download PDF

Info

Publication number
ES2394349A8
ES2394349A8 ES201231343A ES201231343A ES2394349A8 ES 2394349 A8 ES2394349 A8 ES 2394349A8 ES 201231343 A ES201231343 A ES 201231343A ES 201231343 A ES201231343 A ES 201231343A ES 2394349 A8 ES2394349 A8 ES 2394349A8
Authority
ES
Spain
Prior art keywords
treatment
receptor agonists
adrenergic receptor
pulmonary hypertension
selective beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201231343A
Other languages
English (en)
Other versions
ES2394349B1 (es
ES2394349A1 (es
Inventor
Borja IBÁÑEZ CABEZA
Ana GARCÍA-ÁLVAREZ
Valentín FUSTER CARULLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital Clinic de Barcelona
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Original Assignee
Hospital Clinic de Barcelona
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201231343A priority Critical patent/ES2394349B1/es
Application filed by Hospital Clinic de Barcelona, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III filed Critical Hospital Clinic de Barcelona
Publication of ES2394349A1 publication Critical patent/ES2394349A1/es
Publication of ES2394349A8 publication Critical patent/ES2394349A8/es
Priority to PCT/ES2013/070611 priority patent/WO2014033343A1/es
Priority to DK13785891.6T priority patent/DK2891490T3/da
Priority to ES13785891T priority patent/ES2863749T3/es
Priority to US14/424,861 priority patent/US10532038B2/en
Priority to EP13785891.6A priority patent/EP2891490B1/en
Priority to JP2015529082A priority patent/JP6539206B2/ja
Application granted granted Critical
Publication of ES2394349B1 publication Critical patent/ES2394349B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar.#La presente invención se relaciona con el uso de agonistas selectivos de receptores beta-3 adrenérgicos en el tratamiento y/o la prevención de la hipertensión pulmonar.
ES201231343A 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar Withdrawn - After Issue ES2394349B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
PCT/ES2013/070611 WO2014033343A1 (es) 2012-08-29 2013-08-28 Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
JP2015529082A JP6539206B2 (ja) 2012-08-29 2013-08-28 肺高血圧症の治療のためのベータ−３アドレナリン受容体アゴニストの使用
DK13785891.6T DK2891490T3 (da) 2012-08-29 2013-08-28 Beta-3 adrenoceptor-agonister til behandlingen af pulmonal hypertension på grund af sygdom i venstre side af hjertet
ES13785891T ES2863749T3 (es) 2012-08-29 2013-08-28 Agonistas de adrenoreceptores beta-3 para el tratamiento de hipertensión pulmonar debida a cardiopatía izquierda
US14/424,861 US10532038B2 (en) 2012-08-29 2013-08-28 Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension
EP13785891.6A EP2891490B1 (en) 2012-08-29 2013-08-28 Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension due to left heart disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar

Publications (3)

Publication Number Publication Date
ES2394349A1 ES2394349A1 (es) 2013-01-30
ES2394349A8 true ES2394349A8 (es) 2013-04-25
ES2394349B1 ES2394349B1 (es) 2013-11-04

Family

ID=47520452

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201231343A Withdrawn - After Issue ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
ES13785891T Active ES2863749T3 (es) 2012-08-29 2013-08-28 Agonistas de adrenoreceptores beta-3 para el tratamiento de hipertensión pulmonar debida a cardiopatía izquierda

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13785891T Active ES2863749T3 (es) 2012-08-29 2013-08-28 Agonistas de adrenoreceptores beta-3 para el tratamiento de hipertensión pulmonar debida a cardiopatía izquierda

Country Status (6)

Country Link
US (1) US10532038B2 (es)
EP (1) EP2891490B1 (es)
JP (1) JP6539206B2 (es)
DK (1) DK2891490T3 (es)
ES (2) ES2394349B1 (es)
WO (1) WO2014033343A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
AU2022249315A1 (en) * 2021-03-31 2023-10-05 B3Ar Therapeutics, Inc. Compositions of micronized solabegron and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
DE3061205D1 (en) 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
DE3061334D1 (en) 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
PT82120B (en) 1985-03-01 1988-06-16 Beecham Group Plc Process for preparing veterinary formulations containing ethanolamine derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
IT1204416B (it) 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
ATE144139T1 (de) 1989-06-13 1996-11-15 Sanofi Sa Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
GB8925032D0 (en) 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
EP0590793B1 (en) 1992-08-31 1999-10-13 Sankyo Company Limited Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CA2145257A1 (en) 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
ES2159648T3 (es) 1994-11-29 2001-10-16 Dainippon Pharmaceutical Co Derivado de indol.
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
TR199800521T1 (xx) 1995-09-21 1998-06-22 Eli Lilly And Company Se�imli beta3 adrenerjik agonistler.
JP3926390B2 (ja) 1995-10-26 2007-06-06 三菱ウェルファーマ株式会社 β３作業薬として有用なフェニルエタノールアミン化合物、その製法およびその製造における中間体
EP0882707B1 (en) 1996-01-10 2003-10-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
EA199900692A1 (ru) 1997-01-28 2000-02-28 Мерк Энд Ко., Инк. БЕНЗОЛСУЛЬФАМИДЫ ТИАЗОЛА КАК βАГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА И ОЖИРЕНИЯ
DE997458T1 (de) 1997-07-03 2001-03-01 Asahi Chemical Ind Tricyclische verbindungen mit gesättigten ringen und diese enthaltende medizinische zubereitungen
SV2002000522A (es) 2000-07-13 2002-10-24 Lilly Co Eli Agosnistas adrenergicos beta3 ref. x-13921
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US20040242485A1 (en) 2003-05-30 2004-12-02 Takashi Kadowaki Compositions and methods for the amelioration of leptin resistance
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
CN102764438A (zh) 2012-01-30 2012-11-07 林曙光 β3肾上腺素受体激动剂的新用途

Also Published As

Publication number Publication date
US10532038B2 (en) 2020-01-14
ES2394349B1 (es) 2013-11-04
WO2014033343A1 (es) 2014-03-06
EP2891490A1 (en) 2015-07-08
JP6539206B2 (ja) 2019-07-03
US20150374655A1 (en) 2015-12-31
DK2891490T3 (da) 2021-03-15
EP2891490B1 (en) 2020-12-09
WO2014033343A9 (es) 2014-04-24
JP2015526497A (ja) 2015-09-10
ES2863749T3 (es) 2021-10-11
ES2394349A1 (es) 2013-01-30

Similar Documents

Publication Publication Date Title
HK1254724A1 (zh) 用於燃氣輪機的分區的氨洩漏催化劑
CL2015001055A1 (es) Composiciones para lavado de ropa; y uso de dicha composicion.
FR2982155B1 (fr) Composition cosmetique comprenant au moins un alcoxysilane
CL2014000459A1 (es) Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar.
BR112015001841A2 (pt) filete ou listra de segurança, processo para fazer o mesmo ,substrato de segurança, processo para fazer o mesmo , uso do filete ou listra de segurança e documento de segurança.
BR112015009718A2 (pt) composição de matéria e artigo.
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
BR112014009178A2 (pt) métodos, uso, receptor e invenção
BR112015003927A2 (pt) filete ou listra de segurança, processo para fazer o filete ou listra de segurança, uso do filete ou listra de segurança, documento de segurança e processo para fazer o substrato de segurança.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
DK2812341T3 (da) C-terminale hsp90-inhibitorer
ES2394349A8 (es) Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
CO7071125A2 (es) Composiciones, síntesis y métodos para el uso de derivados de fenilcicloalquilmetilamino
GB2513310B (en) Determination of interfacial or surface tension
BR112015002540A2 (pt) eprotirome para uso na prevenção e/ou tratamento de transtornos capilares e composições do mesmo.
ES1074474Y (es) Calzado para uso ludico o deportivo
CO6930361A2 (es) Composición para ser aplicada a la piel, y uso de la misma
CL2015001116A1 (es) Composición y uso de dimeros de alquil cetena hidrogenados.
CL2013003785A1 (es) Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos
ES2464872B1 (es) Composición para el control y la eliminación de biofilms
ES1077809Y (es) Calzado para uso lúdico o deportivo
ES1078130Y (es) Clip para sujeción de toallas, pareos o similares en distintos terrenos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2394349

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20131104

FA2A Application withdrawn

Effective date: 20140318